Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

S'inscrire

ATNM Actinium Pharmaceuticals Inc

7,90

0,00 (0,00%)

Après les heures de négociation

Dernière mise à jour : 01:41:13

Retardé de 15 minutes

Form EFFECT - Notice of Effectiveness

Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024

Plus de graphiques de la Bourse Actinium Pharmaceuticals

Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024

Plus de graphiques de la Bourse Actinium Pharmaceuticals

Actualités Actinium Pharmaceuticals Inc

Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
Jeudi 25 Juillet 2024 ( il y a 1 jour) • PR Newswire (US)

Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US
Jeudi 25 Juillet 2024 ( il y a 2 jours) • PR Newswire (US)

Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
Lundi 17 Juin 2024 ( il y a 1 mois) • PR Newswire (US)

Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial
Vendredi 14 Juin 2024 ( il y a 1 mois) • PR Newswire (US)

Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Mardi 11 Juin 2024 ( il y a 1 mois) • PR Newswire (US)

Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Lundi 10 Juin 2024 ( il y a 2 mois) • PR Newswire (US)

Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
Mercredi 15 Mai 2024 ( il y a 2 mois) • PR Newswire (US)

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phas
Mercredi 15 Mai 2024 ( il y a 2 mois) • PR Newswire (US)

Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Lundi 13 Mai 2024 ( il y a 2 mois) • PR Newswire (US)

Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern
Mardi 7 Mai 2024 ( il y a 3 mois) • PR Newswire (US)

Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Jeudi 18 Avril 2024 ( il y a 3 mois) • PR Newswire (US)

Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual
Lundi 1 Avril 2024 ( il y a 4 mois) • PR Newswire (US)

Plus d'articles sur Actinium Pharmaceuticals Inc

Societe Generale

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales